Article information
Full text is only aviable in PDF
References
[1.]
Okafer MC, Pharm D. Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy 2003; 23(4), Available at: http://www.medscape.com, Posted on: 05/01/2003; Accessed on: Nov 6, 2009.
[2.]
L. Fogagnolo, E.M. de Souza, M.L. Cintra, P.E.N.F. Velho.
Vasculonecrotic reactions in leprosy.
Braz J Infect Dis, 11 (2007), pp. 378-382
[3.]
I.M.C. Costa, L.B. Kawano, C.P. Pereira, L.S.C. Nogueira.
Lucio's phenomenon: case report and review of the literature.
Int J Dermatol, 44 (2005), pp. 566-571
[4.]
O. Welsh, M. Gómez, C. Mancias, S. Ibarra-Leal, L.E. Millikan.
A new therapeutic approach to type II leprosy reaction.
Int J Dermatol, 38 (1999), pp. 931-933
[5.]
J. Revuz, J.C. Guillaume, M. Janier, et al.
Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.
Arch Dermatol, 126 (1990), pp. 923-927
[6.]
M. Hamza.
Behçet's disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide.
Clin Exp Rheumatol, 8 (1990), pp. 427
[7.]
J. Knop, G. Bonsmann, R. Happle, et al.
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Br J Dermatol, 108 (1983), pp. 461-466
[8.]
D. Stirling.
Thalidomide and its impact in dermatology.
Semin Cutan Med Surg, 17 (1998), pp. 231-242
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
